Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

147.93 -1.63 (-1.09%)
Streaming Delayed Price Updated: 12:47 PM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Investor patience tested as pharmaceutical stocks take a tumble
The healthcare sector faces a selloff as pharmaceutical giants report lackluster earnings; even Amgen's strong results failed to prevent selling in the sector 
Via MarketBeat
J&J stock down as business unit mulls talc-related bankruptcy
Johnson & Johnson stock fell in the past week as talc-related lawsuits weigh on a subsidiary, which is mulling bankruptcy to mitigate payouts and settlements. 
Via MarketBeat
Topics Bankruptcy Lawsuit
Exposures Financial Legal
Are These 3 Dividend Aristocrats Undervalued Hidden Gems?
Dividend aristocrats Caterpillar, NextEra, and Clorox have shown resilience in challenging times. These may offer opportunities as they are trading off highs. 
Via MarketBeat
Exposures COVID-19
Johnson & Johnson Announces Departure of Ashley McEvoy, Tim Schmid Named Executive Vice President, Worldwide Chairman of MedTech
From Johnson & Johnson
Via Business Wire
Johnson & Johnson (NYSE: JNJ) is One of Monday Morning’s Most Active Stocks
Via Investor Brand Network
The Value Deepens for Medtech Stocks: Reversal Imminent
MedTech stocks are performing well and supported by pent-up demand, yet share prices are trading at significant and often historical lows. 
Via MarketBeat
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2023
From Johnson & Johnson
Via Business Wire
Oversold and Overextended, Abbott Laboratories is a Great Buy
Abbott Laboratories rises on solid results and guidance; the value and dividend are at the best levels in years, and the sell-side is buying. 
Via MarketBeat
Exposures COVID-19
Johnson & Johnson Reports Q3 2023 Results
From Johnson & Johnson
Via Business Wire
Steroids Market Is Set to Fly High in Years to Come : Pfizer, Johnson & Johnson, Bayer
Stay up to date with Steroids Market research offered by HTF MI. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
3 Undervalued Healthcare Stocks to Watch as Sector Struggles
As the healthcare sector slumps, several major stocks, including Zimmer Biomet, Moderna, and Illumina, appear undervalued in contrast to their intrinsic worth. 
Via MarketBeat
3 Blue Chip Safe Havens to Shield Your Portfolio
As the market experiences heightened volatility and uncertainty, it's worth exploring defensive stocks like JNJ, PG, and VZ for stability amid the uncertainty. 
Via MarketBeat
Topics ETFs Economy
Exposures Economy Interest Rates
3 Reasons SharkNinja Is Swimming Toward New Highs
Shares of SharkNinja, Inc. are up more than 50% since August 4th — and becoming a popular momentum bet amongst retail traders. 
Via MarketBeat
Flee to Healthcare Stocks if Recession Rears its Head?
In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends. 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
The Breakthrough Therapy Aiming To Solve The World’s Mental Health Crisis
EQNX::TICKER_START (NYSE:JNJ),(NYSE:ABBV),(NASDAQ:ATAI),(NASDAQ:CMPS),(NASDAQ:MNMD) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Economy
Exposures Economy Product Safety
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
From Johnson & Johnson
Via Business Wire
Johnson & Johnson Marks New Era as Global Healthcare Company With Updated Visual Identity
From Johnson & Johnson
Via Business Wire
Dividend Growth Rates and How to Calculate Them
Via MarketBeat
7 Best Blue Chip Stocks to Buy Now
Blue-chip stocks are the stocks of well-known, high-quality industry leaders. Learn more about our top picks for the best blue chip stocks to buy now. 
Via MarketBeat
Global Dry Eye Syndrome Treatment Market Expected to Reach $11.26 Billion By 2030
EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:ALC),(NYSE:BLCO),(NYSE:JNJ),(OTCQX:RHHBY) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
3 Stocks Awaiting Winter Winds of Opportunity
The change in seasons favors specific stocks like JNJ, GOOS, and MTN, which exhibit growth patterns tied to seasonal changes. 
Via MarketBeat
J&J Spinoff Kenvue is the New Dividend Aristocrat on the Block
Newly public company Kenvue, a spinoff from Johnson & Johnson, joins the ranks of dividend aristocrats, offering a 3.57% yield, and 2022 sales of $15 billion. 
Via MarketBeat
Topics ETFs
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
Pharmaceutical stocks are holding steady as Medicare price negotiations approach, but industry diversification and innovation support future growth prospects. 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Johnson & Johnson Announces Updated Financials and 2023 Guidance Following Completion of the Kenvue Separation
From Johnson & Johnson
Via Business Wire
3 High Short Interest Stocks that Investors are Getting Wrong
Heavy short interest can be a sell signal, but these three stocks have bullish stories that make them attractive investments despite heavy short interest 
Via MarketBeat
Exposures Fossil Fuels
Disney's Big Breakup? Wall Street, Iger Ponder A Magical Split
Disney is facing decisions about a potential split, with a focus on core businesses like streaming, parks, and film studios. CEO Bob Iger remains noncommittal. 
Via MarketBeat
Topics Earnings
Exposures Financial
Johnson & Johnson Announces Final Results of Exchange Offer and Finalizes Separation of Kenvue Inc.
From Johnson & Johnson
Via Business Wire
Johnson & Johnson to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
From Johnson & Johnson
Via Business Wire
Johnson & Johnson Announces Preliminary Results of Kenvue Inc. Exchange Offer
From Johnson & Johnson
Via Business Wire
Antiepileptic Drugs Market to Witness Massive Growth by 2028 : Johnson & Johnson, Sumitomo Pharma, Sanofi
Stay up to date with Antiepileptic Drugs Market research offered by HTF MI. Check how key trends and emerging drivers are shaping this industry growth. 
Via SBWire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.